Jun13133
Jun13133 is a potent Enterovirus D68 3C Protease (EV-D68 3Cpro) inhibitor with an IC50 of 28.6 nM. Jun13133 exhibits broad-spectrum and potent anti-enterovirus activity, including against EV-D68 (EC50 = 8.2~9.9 nM) and EV-A71 (EC50 = 17.1 nM). Jun13133 covalently binds to the conserved catalytic residue Cys147 of EV-D68 3Cpro, thereby competitively inhibiting and blocking the ability of 3Cpro to catalytically cleave the viral polyprotein, thus inhibiting viral replication. Jun13133 can be used for research on severe respiratory disease and acute flaccid myelitis caused by EV-D68.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C27H30FN4NaO8S
- Masse moléculaire:612.60
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
[1]|
EV-D68 3Cpro 28.6 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RD | EC50 |
8.2 nM
|
Antiviral activity against EV-D68 strain US/MO/14-18947 in human rhabdomyosarcoma RD cells assessed as plaque area reduction after 60 hrs incubation at 33 °C by crystal violet staining.
Antiviral activity against EV-D68 strain US/MO/14-18947 in human rhabdomyosarcoma RD cells assessed as plaque area reduction after 60 hrs incubation at 33 °C by crystal violet staining.
|
acs.jmedchem.6c00818 |
| RD | EC50 |
9.9 nM
|
Antiviral activity against EV-D68 strain US/MO/14-18949 in human rhabdomyosarcoma RD cells assessed as plaque area reduction after 60 hrs incubation at 33 °C by crystal violet staining.
Antiviral activity against EV-D68 strain US/MO/14-18949 in human rhabdomyosarcoma RD cells assessed as plaque area reduction after 60 hrs incubation at 33 °C by crystal violet staining.
|
acs.jmedchem.6c00818 |
| RD | EC50 |
9.0 nM
|
Antiviral activity against EV-D68 strain US/IL/14-18952 in human rhabdomyosarcoma RD cells assessed as plaque area reduction after 60 hrs incubation at 33 °C by crystal violet staining.
Antiviral activity against EV-D68 strain US/IL/14-18952 in human rhabdomyosarcoma RD cells assessed as plaque area reduction after 60 hrs incubation at 33 °C by crystal violet staining.
|
acs.jmedchem.6c00818 |
| RD | EC50 |
8.5 nM
|
Antiviral activity against EV-D68 strain US/IL/14-18956 in human rhabdomyosarcoma RD cells assessed as plaque area reduction after 60 hrs incubation at 33 °C by crystal violet staining.
Antiviral activity against EV-D68 strain US/IL/14-18956 in human rhabdomyosarcoma RD cells assessed as plaque area reduction after 60 hrs incubation at 33 °C by crystal violet staining.
|
acs.jmedchem.6c00818 |
| RD | EC50 |
9.7 nM
|
Antiviral activity against EV-D68 strain US/KY/14-18953 in human rhabdomyosarcoma RD cells assessed as plaque area reduction after 60 hrs incubation at 33 °C by crystal violet staining.
Antiviral activity against EV-D68 strain US/KY/14-18953 in human rhabdomyosarcoma RD cells assessed as plaque area reduction after 60 hrs incubation at 33 °C by crystal violet staining.
|
acs.jmedchem.6c00818 |
| RD | EC50 |
17.1 nM
|
Antiviral activity against EV-A71 strain Tainan/4643/1998 in human rhabdomyosarcoma RD cells assessed as plaque area reduction after 60 hrs incubation at 33 °C by crystal violet staining.
Antiviral activity against EV-A71 strain Tainan/4643/1998 in human rhabdomyosarcoma RD cells assessed as plaque area reduction after 60 hrs incubation at 33 °C by crystal violet staining.
|
acs.jmedchem.6c00818 |
| RD | CC50 |
52.4 μM
|
Cytotoxicity against human rhabdomyosarcoma RD cells assessed as viability reduction after 60 hrs incubation at 33 °C by neutral red uptake assay.
Cytotoxicity against human rhabdomyosarcoma RD cells assessed as viability reduction after 60 hrs incubation at 33 °C by neutral red uptake assay.
|
acs.jmedchem.6c00818 |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Swiss Webster (pups, postnatal day 1-2, 1.5-2.0 g)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; once daily; starting 24 h post-infection for 10 days
-
Result:Ameliorated paralysis induced by viral infection, with paralysis scores significantly lower than those of the vehicle control group.
Prevented excessive weight loss in mice (weights were significantly higher on days 12-14 post-infection compared to the control group), indicating reduced disease severity.
Reduced viral titers in the spinal cord at 4 and 7 days post-infection (virus was almost undetectable).
Decreased viral titers in the injected quadriceps (infected muscle tissue) at 4 and 7 days post-infection.
Chemical Information
-
Masse moléculaire 612.60
-
Formule C27H30FN4NaO8S
-
SMILES
FC(C=C1)=CC=C1C[C@@H](C(N[C@H](C(S(=O)(O[Na])=O)O)C[C@@H]2CCCNC2=O)=O)NC(C3=CC4=C(C=CC=C4OC)N3)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Jun13133 Related Classifications
HY-190797 Related Classifications
Powered by Bioz